Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 13, 2026 1 hour, 50 minutes ago
Medical News: Cardiovascular disease remains the world’s leading killer, but a new wave of research is uncovering an unexpected group of enzymes that may hold the key to better treatments. Scientists are now focusing on dual-specificity tyrosine-regulated kinases, or DYRKs, as powerful regulators of how the heart responds to injury, stress, and long-term damage. Findings from a newly published scientific review suggest these enzymes could become central targets for future therapies aimed at heart attacks, heart failure, and cardiac fibrosis.
Scientists uncover enzymes that could reshape future heart disease treatments
What Are DYRKs And Why Do They Matter
DYRKs are specialized enzymes that control how cells grow, survive, and repair themselves. Unlike many other proteins, they can activate themselves and continue working without constant external signals. This unique behavior allows them to stay active during stressful conditions such as reduced blood flow or oxygen deprivation in the heart. According to the review, these enzymes influence multiple critical processes including cell death, inflammation, energy metabolism, and tissue remodeling - key drivers of heart disease progression.
The research team from the Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, and Hunan Normal University in Changsha, China, emphasized that different DYRK family members play distinct roles depending on the type of heart condition and stage of disease.
How DYRKs Influence Heart Damage and Repair
One of the most important discoveries is how DYRK1A affects heart recovery after a heart attack. Normally, adult heart cells have very limited ability to regenerate. However, the study found that blocking DYRK1A can encourage heart cells to re-enter the cell cycle and multiply, improving heart function after injury. This opens the door to therapies that could help the heart repair itself more effectively.
At the same time, DYRKs are deeply involved in harmful processes. For example, DYRK1A can worsen damage during ischemia - reperfusion injury - a condition where restoring blood flow paradoxically causes further harm. It does this by promoting ferroptosis, a destructive form of cell death driven by iron and oxidative stress.
DYRK2, another member of the family, plays a different role by limiting excessive cell growth and controlling protein production. However, under chronic stress, its protective effects may weaken, allowing harmful heart enlargement to progress.
The Double-Edged Role in Heart Disease
Perhaps the most striking finding is that DYRKs can act as both protectors and aggressors depending on the situation. In some cases, they prevent excessive cell growth and reduce stress damage. In others, they contribute to fibrosis, heart failure, and metabolic dysfunction.
For instance, DYRK1A can suppress harmful signaling pathways that lead to cardiac enlargement, yet prolonged activation may worsen long-term heart remodeling. Similarly, DYRK1B has been linked to energy failure in heart cells by disrupting mitochondrial function, a key factor in
advanced heart failure.
This
Medical News report highlights that these conflicting roles make DYRKs both promising and challenging targets for drug development.
New Drug Possibilities on The Horizon
Researchers have already begun testing compounds that inhibit DYRK activity. Early experimental drugs such as harmine and leucettine derivatives have shown the ability to improve heart function, reduce scarring, and promote regeneration in animal models. However, these treatments are still in early stages and have not yet reached clinical trials for heart disease.
A major challenge is ensuring that therapies target specific DYRK types without affecting others, as broad inhibition could lead to unwanted side effects, including risks in the brain or potential cancer-related concerns.
Future Outlook and Conclusions
The discovery of DYRK enzymes as central regulators of heart disease represents a major shift in cardiovascular research. These proteins sit at the crossroads of multiple disease pathways, making them highly attractive therapeutic targets. However, their complex and sometimes opposing roles mean that future treatments must be carefully timed, precisely targeted, and tailored to individual patients.
Importantly, scientists suggest that short-term inhibition of certain DYRKs after acute events like heart attacks could promote healing, while long-term strategies may require restoring balance rather than complete suppression. Advances in targeted drug delivery systems, including gene therapies and RNA-based treatments, may help overcome current limitations.
In conclusion, DYRK enzymes are emerging as powerful but complex players in cardiovascular health. While much remains to be understood, their ability to influence regeneration, metabolism, and cell survival places them at the forefront of next-generation heart therapies. With further research, these enzymes could transform how doctors treat some of the deadliest heart conditions.
The study findings were published in the peer reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/27/8/3456
For the latest on heart diseases, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/cardiology
Share
Tweet
Share
